Share this with FacebookShare this with TwitterShare this with LinkedInEmail this pagePrint this page
Healio: Two studies provide further positive outcomes for empagliflozin in HF
Among patients with heart failure, empagliflozin lowered diastolic pulmonary artery pressure and was effective at reducing cardiovascular death and heart failure hospitalizations regardless of sacubitril/valsartan use, researchers reported.
Dr. Mikhail Kosiborod, vice president of research at Saint Luke's Health System, detailed the results of the EMBRACE-HF study looking at the impact of empagliflozin in patients with heart failure and higher diastolic pulmonary artery pressure.
Read the full Healio article: Two studies provide further positive outcomes for empagliflozin in HF